Ovarian And Endometrial Cancers
WHWKWhitehawk TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for HWK-016 (MUC16 Targeted ADC) in Ovarian And Endometrial Cancers. The expected timing is based on the latest available company guidance and may change.
01/08/26:- IND submitted Dec 2025 for HWK-016; Phase 1 MUC16 ADC trial plans to start recruiting Q1 2026; data Early 2027. 03/12/26:- Ph1 HWK-016 ovarian/endometrial trial actively recruiting; initial Ph1 data expected H1 2027. 03/17/26:- Preclinical HWK-016 minisymposium oral at AACR 2026 on April 19, 2026. 04/10/26:- SGO 2026 posters highlight MUC16 analysis; Phase 1 NCT07470853 ongoing; initial data expected H1 2027. 05/07/26:- Ph1 HWK-016 trial enrollment ongoing; initial data timing reiterated for H1 2027. 08/06/26:- Ph1 HWK-016 enrollment continues; initial results expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.